plazomicin

Plazomicin is a next-generation aminoglycoside antibiotic developed to treat complicated urinary tract infections (cUTI), including pyelonephritis, particularly in patients with limited or no alternative treatment options. It is synthetically derived from sisomicin and was designed to evade most clinically relevant aminoglycoside-modifying enzymes that confer resistance to older aminoglycosides. Plazomicin exerts its antibacterial effect by binding exclusively to the 16S rRNA A-site of the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis and leading to rapid bactericidal activity. This mechanism disrupts mRNA translation fidelity, resulting in cell death. Plazomicin demonstrates efficacy against multidrug-resistant pathogens such as carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase (ESBL)-producing bacteria[1][6][7][8]. It is administered intravenously and was approved by the FDA in June 2018 for adult patients[7].

Brand names

Zemdri

Other names

plazomicinaplazomicine